Status:
TERMINATED
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
Lead Sponsor:
Incyte Corporation
Collaborating Sponsors:
Mirati Therapeutics Inc.
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to evaluate the safety and tolerability of INCB099280 in combination with adagrasib and to establish the MTD or identify RDE(s) for the combination of INCB099280 and adagr...
Eligibility Criteria
Inclusion
- KRASG12C-mutated solid malignancy determined by a sponsor-approved assay using either tumor tissue or ctDNA.
- Histologically confirmed malignant solid tumor with locally advanced and/or metastatic disease.
- Only participants with NSCLC will be enrolled into Part 2 Cohort A.
- Only participants with CRC will be enrolled into Part 2 Cohort B.
- Part 1: Disease progression on or after at least 1 prior systemic treatment.
- Part 2 (Cohort A - NSCLC): Received an anti-PD-(L)1-containing regimen and platinum based chemotherapy regimen either concurrently or sequentially
- Part 2 (Cohort B - CRC): Received at least 1 line of systemic therapy that includes the combination of fluoropyrimidine-based chemotherapy (in combination with oxaliplatin and/or irinotecan) and either a vascular endothelial growth factor-targeting monoclonal antibody or an anti-epidermal growth factor receptor monoclonal antibody (if RAS wild type). Participants with MSI-H/dMMR CRC must also have received a prior immune checkpoint inhibitor approved for this indication.
- Measurable disease according to RECIST v1.1.
- Eastern Cooperative Oncology Group performance status of 0 or 1.
- Estimated life expectancy \> 3 months.
- Willingness to avoid pregnancy.
Exclusion
- Known additional malignancy that is progressing or requires active treatment.
- Central nervous system (CNS) metastases requiring treatment and/or leptomeningeal disease.
- Part 2 only: Prior treatment with an approved or investigational agent targeting KRASG12C.
- Toxicity from prior therapy that has not recovered to protocol-defined limits.
- Received thoracic radiation of \> 30 Gy within 6 months of the first dose of study treatment.
- Participation in another interventional clinical study.
- History or evidence of interstitial lung disease, including noninfectious pneumonitis.
- Presence of gastrointestinal condition that may affect drug absorption.
- Active autoimmune disease requiring systemic treatment, including corticosteroids exceeding a daily dose of 10 mg of prednisone or equivalent.
- Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy exceeding a daily dose of 10 mg of prednisone or equivalent.
- Active infection requiring systemic therapy.
- History of organ transplantation, including allogeneic stem cell transplantation.
- Receipt of systemic antibiotics within 28 days of the first dose of study treatment.
- Probiotic usage is prohibited during screening and throughout the study treatment period.
- Received a live vaccine within 28 days of the planned start of study drug.
- Laboratory values outside the Protocol-defined ranges.
- Other protocol-defined Inclusion/Exclusion Criteria may apply.
Key Trial Info
Start Date :
December 28 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 11 2025
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT06039384
Start Date
December 28 2023
End Date
July 11 2025
Last Update
August 3 2025
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Valkyrie Clinical Trials
Los Angeles, California, United States, 90067
2
Banner Md Anderson Cancer Center
Greeley, Colorado, United States, 80631
3
Henry Ford Health System
Detroit, Michigan, United States, 48202
4
Mary Crowley Cancer Research Centers McCrc Headquarters
Dallas, Texas, United States, 75251